VO
Vivo Opportunity, LLC
Other
内部人交易记录
其他尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by Vivo Opportunity, LLC. Officer active across 4 companies, notably Sierra Oncology, Inc.. In total, 18 disclosures have been logged. Breakdown: 10 buys · 4 sells. Total volume traded: €110.5m. History available since 26 January 2022. The latest transaction was filed on 14 July 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Vivo Opportunity, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
493 股@ US$1.550.0092% mcap2.4% 占其流量Common SharesSEC:0001213900-26-078891:1
4,882 股@ US$1.550.091% mcap23.8% 占其流量Common SharesSEC:0001213900-26-078891:0
13,761 股@ US$1.550.26% mcap66.9% 占其流量Common SharesSEC:0001213900-26-078891:2
1,389 股@ US$1.550.026% mcap6.8% 占其流量Common SharesSEC:0001213900-26-078891:3
19 股@ US$1.550.0004% mcap0.1% 占其流量Common SharesSEC:0001213900-26-078891:4
2 股@ US$1.550.0000% mcap0.0% 占其流量Common SharesSEC:0001213900-26-078891:5
400,000 股@ US$65.8025.1% 占其流量Common StockSEC:0001013762-25-004322:0
500,000 股@ US$48.7322.4% 占其流量Common StockSEC:0001213900-24-074051:0
750,000 股@ US$47.8034.4% 占其流量Common StockSEC:0001213900-24-038343:0
136,255 股@ US$6.997.7% 占其流量Common StockSEC:0001213900-24-030020:0
5,215,000 股@ US$2.5012.8% 占其流量Common StockSEC:0001013762-23-001637:0
3,203,093 股@ US$1.7529.9% 占其流量Common StockSEC:0001213900-23-080555:0
758,620 股@ US$7.2545.2% 占其流量Common StockSEC:0001213900-22-082664:0
600,000 股@ US$3.6018.8% 占其流量Common StockSEC:0001213900-22-054888:0
1,123,021 股@ US$2.9828.3% 占其流量Common StockSEC:0001213900-22-048763:0
161,712 股@ US$55.0017.8% 占其流量Common StockSEC:0001213900-22-036724:0
800,000 股@ US$27.0068.8% 占其流量Common StockSEC:0001213900-22-004647:0
24,996 股@ US$13.201.0% 占其流量Common StockSEC:0001213900-22-004318:0
About Vivo Opportunity, LLC
Vivo Opportunity, LLC has filed 18 filings in total. Among the recent filings held, purchases amount to EUR 29987779 and sales to EUR 89027337, over the period from 2022-01-28 to 2026-07-16. The companies mentioned are InMed Pharmaceuticals Inc. as 10% Owner, Soleno Therapeutics INC, Terns Pharmaceuticals, Inc., and Sierra Oncology, Inc. as Director.